Benutzerspezifische Werkzeuge

Klinische Studien

Klinische Studien

Für Patienten

In unserem Studienzentrum liegt der Schwerpunkt auf Studien der Phase II und III.

  • aktuelle klinische Studien zu folgenden Indikationen:
Prostatakarzinom

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with
Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer

CheckMate 7DX

A confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unenhanced MRI in reference to histopathology in newly-diagnosed prostate cancer (PCA) patients, scheduled for radical prostatectomy (RP) wih extended pelvic lymph node dissection (ePLND)

SPL-01-001

A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy

ADAM

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Keynote-991
Urothelkarzinom (Harnblase)

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC)

Keynote-866

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer

Keynote-B15
Urothelkarzinom (Harnblase und oberer Harntrakt)

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

THOR
Nierenzellkarzinom

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

MK6482-005

A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Clear-Cell Variant Renal Cell Carcinoma Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

Cabopoint

weitere Informationen finden Sie unter: ClinicalTrials.gov

Sofern Sie in diesem Zusammenhang Fragen haben oder eventuell an einer der Studien in unserer Klinik teilnehmen möchten, setzen Sie sich bitte mit uns in Verbindung.

Kontakt:

Platzhalter Bild

Pit Raupach

Studienkoordinator

+49- 0351 458-4425 +49- 0351 458-7280